SCHEMBL11986178

SCHEMBL11986178

Cc1nc(C#N)cc(Br)c1C

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.34
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
ADRA2A P08913 1/20 0.31
ADORA2A P29274 1/20 0.31
HTT P42858 1/20 0.31
HSD17B10 Q99714 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
MBOAT4 Q96T53 1/20 0.31
EGLN2 Q96KS0 2/20 0.31
NQO2 P16083 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30
TTR P02766 1/20 0.30
ALB P02768 1/20 0.30
NQO1 P15559 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29331580 0.80 ALDH1A1 (0.35) LMNAKDM4EMEN1KMT2AALDH1A1
SCHEMBL30938639 0.80 ALDH1A1 (0.35) LMNAKDM4EMEN1KMT2AALDH1A1
SCHEMBL25239817 0.80 MBOAT4 (0.37) KDM4EMEN1KMT2AHTTALDH1A1
SCHEMBL31161591 0.80 MEN1 (0.36) KDM4EMEN1KMT2AHTTALDH1A1
SCHEMBL30478351 0.80 MBOAT4 (0.37) KDM4EMEN1KMT2AHTTALDH1A1
SCHEMBL11986180 0.78 KDM4E (0.35) LMNAKDM4EMEN1KMT2AADRA2A
SCHEMBL14853157 0.75 KDM4E (0.33) LMNAKDM4EMEN1KMT2AMBOAT4
SCHEMBL11986176 0.75 TTR (0.34) KDM4EADRA2AADORA2AHTTHSD17B10
SCHEMBL11942293 0.75 HSD17B10 (0.38) KDM4EADRA2AADORA2AHTTHSD17B10
SCHEMBL11986175 0.75 ALDH1A1 (0.38) KDM4EMEN1KMT2AADRA2AADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9376436-B2 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators Convergence Pharmaceuticals Limited (GB) 2016-06-28 US disclosed
EP-2794612-B1 2-(PYRIDIN-2YL)-1,7-DIAZA-SPIRO[4.4]NONANE-6-ONE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS CONVERGENCE PHARMACEUTICALS (GB) 2016-04-06 EP disclosed
US-20150225400-A1 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS Convergence Pharmaceuticals Limited (GB) 2015-08-13 US disclosed
EP-2794612-A1 2 - (PYRIDIN- 2YL) - 1, 7 -DIAZA- SPIRO [4.4]NONANE- 6 -ONE COMPOUNDS AS VOLTAGE - GATED SODIUM CHANNELS MODULATORS Convergence Pharmaceuticals Limited (GB) 2014-10-29 EP disclosed
WO-2013093497-A1 2 - (PYRIDIN- 2YL) - 1, 7 -DIAZA- SPIRO [4.4] NONANE- 6 -ONE COMPOUNDS AS VOLTAGE - GATED SODIUM CHANNELS MODULATORS Convergence Pharmaceuticals Limited (GB) 2013-06-27 WO disclosed
US-8247431-B2 Heterocyclic hydrazide compound and pesticidal use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-21 US disclosed
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225400-A1 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS SCN1A, SCN2A, SCN1B LMNA 646/4885KDM4E 2376/4885MEN1 2052/4885
US-20100137362-A1 HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME ACHE, CAT, DNPH1 LMNA 3561/4885KDM4E 2297/4885MEN1 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.